ADHERENCE AND PERSISTENCE TO TREATMENT WITH INFLIXIMAB: ANALYSIS OF A PATIENT SUPPORT PROGRAM COHORT IN BRAZIL.
Aniela Bonorino Xexeo Castelo BrancoWilton ArgoloNathalia SantosGabriela HernandezAdriana Maria KakehasiCarlos Walter Sobrado JuniorRichard MelsheimerPublished in: Arquivos de gastroenterologia (2024)
Many patients leave the program without discontinuing IFX, since the 12-month persistence were very different between program and medication estimates, while high adherence rates were observed among patients enrolled in the PSP. Data highlights the benefits of a PSP.
Keyphrases
- emergency department
- quality improvement
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- adverse drug
- healthcare
- type diabetes
- electronic health record
- metabolic syndrome
- patient reported outcomes
- machine learning
- deep learning
- insulin resistance
- artificial intelligence
- patient reported
- smoking cessation